EFFECTIVENESS OF LEVOCARNITINE IN CHILDREN WITH CARDITIS

Abstract

Respiratory diseases are the most common group of diseases among the child population and occupy the first place in the structure of general morbidity of children. The relevance of chronic bronchopulmonary processes, disability and mortality remains. The aim of the study is: to study the effectiveness of levocarnitine in pneumonia in children with carditis. Materials and methods of research. The study involved 40 children aged 1 to 12 years with pneumonia associated with myocarditis who were receiving inpatient treatment in the pediatric departments and pediatric intensive care unit of the Samarkand branch of the Republican Scientific Center for Emergency Medical Care. The patients were divided into 2 groups: Group I, 20 patients – children with pneumonia associated with carditis who received standard therapy; Group II, 20 patients – children with pneumonia who received oral levocarnitine in addition to standard therapy. Conclusions: Levocarnitine has cardioprotective and antioxidant properties, which helps reduce myocardial damage in inflammatory diseases, including carditis, improving the transport of fatty acids into the mitochondria, levocarnitine maintains the energy balance of cells, which is especially important in the combination of pneumonia with carditis, when tissues experience hypoxic and metabolic depletion, levocarnitine can reduce the level of proinflammatory cytokines, which potentially reduces the severity of the inflammatory response in pneumonia and carditis, Levocarnitine helps to normalize heart rhythm, reduce the risk of myocardial dysfunction and improve the general condition of patients with pneumonia against the background of carditis. The use of levocarnitine as part of the complex treatment of pneumonia against the background of carditis can help speed up recovery, reduce the incidence of complications and improve the prognosis for patients.